Bioxytran, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BIXT research report →
Companywww.bioxytraninc.com
Bioxytran, Inc. , a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company's lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing.
- CEO
- David Platt
- IPO
- 2010
- Employees
- 3
- HQ
- Newton, MA, US
Price Chart
Valuation
- Market Cap
- $3.79M
- P/E
- -1.32
- P/S
- 0.00
- P/B
- -0.85
- EV/EBITDA
- -1.70
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 90.64%
- ROIC
- 92.43%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-2,123,077 · 10.29%
- EPS
- $-0.02 · -35.09%
- Op Income
- $-1,854,053
- FCF YoY
- -527.24%
Performance & Tape
- 52W High
- $0.17
- 52W Low
- $0.03
- 50D MA
- $0.04
- 200D MA
- $0.06
- Beta
- -0.77
- Avg Volume
- 339.10K
Get TickerSpark's AI analysis on BIXT
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 14, 25 | Hoberman Alan M | other | 38,588 |
| Aug 12, 25 | Hoberman Alan M | other | 10,417 |
| Nov 18, 25 | Hoberman Alan M | buy | 210,000 |
| Nov 14, 25 | MILANOVA RADKA | other | 38,588 |
| Aug 12, 25 | MILANOVA RADKA | other | 10,417 |
| Nov 14, 25 | CONAWAY DALE H | other | 38,588 |
| Aug 12, 25 | CONAWAY DALE H | other | 10,417 |
| Nov 14, 25 | Utter Anders | other | 38,588 |
| Oct 24, 24 | PLATT DAVID | other | 11,433,448 |
| Oct 24, 24 | PLATT DAVID | other | 14,085,410 |
Our BIXT Coverage
We haven't published any research on BIXT yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate BIXT Report →